Transcode Other Current Liab from 2010 to 2024

RNAZ Stock  USD 0.38  0.04  11.76%   
Transcode Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, Transcode Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.64 and arithmetic mean of  900,659. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
3.5 M
Current Value
3.7 M
Quarterly Volatility
1.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 48.1 K, Tax Provision of 0.0 or Net Interest Income of 15.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Transcode Therapeutics over the last few years. It is Transcode Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Transcode Other Current Liab Regression Statistics

Arithmetic Mean900,659
Geometric Mean138,606
Coefficient Of Variation161.10
Mean Deviation1,219,405
Median35,685
Standard Deviation1,450,969
Sample Variance2.1T
Range3.6M
R-Value0.80
Mean Square Error825.7B
R-Squared0.64
Significance0.0004
Slope258,705
Total Sum of Squares29.5T

Transcode Other Current Liab History

20243.7 M
20233.5 M
20223.1 M
20212.5 M
2020404.9 K

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities3.5 M3.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.